المؤلفون: Christian U. Blank, John B. A. G. Haanen, Doranne L. Hilarius, Michel W. J. M. Wouters, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Rawa K. Ismail, Geke A. P. Hospers, Jesper van Breeschoten, Alfonsus J. M. van den Eertwegh, Rozemarijn S. van Rijn, Jan Willem B. de Groot, Maureen J.B. Aarts, D Piersma, Astrid A M van der Veldt, G. Vreugdenhil, Marion A. M. Stevense-den Boer, Marye Boers-Sonderen, Karijn P M Suijkerbuijk, Olivier J. van Not, Melissa M. De Meza

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D)

المصدر: International Journal of Cancer, 150(5), 816-824. Wiley
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833Test
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancer

مصطلحات موضوعية: Adult, Male, advanced melanoma, Cancer Research, Pediatrics, medicine.medical_specialty, Skin Neoplasms, Coronavirus disease 2019 (COVID-19), IMPACT, nationwide registry, Medical care, Systemic therapy, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], systemic therapy, SDG 3 - Good Health and Well-being, COVID‐19, Humans, Medicine, Stage IIIC, Cancer Therapy and Prevention, Melanoma, Aged, Netherlands, Advanced melanoma, Aged, 80 and over, Control period, Performance status, SARS-CoV-2, business.industry, COVID-19, Middle Aged, medicine.disease, clinical outcomes, Oncology, Female, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6999d1436b905ac42aa992a91b031b28Test
https://hdl.handle.net/2066/244556Test

المؤلفون: Debbie van Baarle, Nynke Y. Rots, Mathilda Jalving, Christian U. Blank, Elisabeth G.E. de Vries, Guus F. Rimmelzwaan, Tatjana T Westphal, Cecile A C M van Els, Anne-Marie C. Dingemans, John B. A. G. Haanen, T. Jeroen N. Hiltermann, Egbert F. Smit, Rudolf S N Fehrmann, Arkajyoti Bhattacharya, Rob van Binnendijk, Astrid A M van der Veldt, Gerco den Hartog, Anke Huckriede, Pia Kvistborg, Corine H. GeurtsvanKessel, Sjoukje F. Oosting, Marion Koopmans, Marieke van der Heiden

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), Microbes in Health and Disease (MHD), Medical Oncology, Radiology & Nuclear Medicine, Virology, Pulmonary Medicine

المصدر: Lancet Oncology, 22(12), 1681-1691. ELSEVIER SCIENCE INC
The Lancet Oncology, 22(12), 1681-1691. Lancet Publishing Group
The Lancet. Oncology

مصطلحات موضوعية: Male, medicine.medical_specialty, Antineoplastic Agents, Antibodies, Viral, Injections, Intramuscular, Cohort Studies, Immunomodulation, Interferon-gamma, Immunogenicity, Vaccine, SDG 3 - Good Health and Well-being, Chemoimmunotherapy, Neoplasms, Surveys and Questionnaires, VACCINES, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, Seroconversion, Adverse effect, Aged, Netherlands, SARS-CoV-2, business.industry, Vaccination, COVID-19, Cancer, Articles, Middle Aged, medicine.disease, Combined Modality Therapy, CANCER, Oncology, Cohort, Female, Immunotherapy, business, Febrile neutropenia, 2019-nCoV Vaccine mRNA-1273, RESPONSES

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b729685410a8953022f09c2f02822a62Test
https://doi.org/10.1016/s1470-2045Test(21)00574-x

المؤلفون: Olivier J. van Not, Rik J. Verheijden, Alfonsus J. M. van den Eertwegh, John B. A. G. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan-Willem B. de Groot, Geke A. P. Hospers, Anna M. Kamphuis, Ellen Kapiteijn, Anne M. May, Melissa M. de Meza, Djura Piersma, Rozemarijn van Rijn, Marion A. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Willeke A. M. Blokx, Michel J. M. Wouters, Karijn P. M. Suijkerbuijk

المساهمون: Medical Oncology, Radiology & Nuclear Medicine, Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: JAMA Oncology. AMER MEDICAL ASSOC
JAMA Oncology
JAMA Oncology, 8(12), 1794-1801. American Medical Association
van Not, O J, Verheijden, R J, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, de Groot, J-W B, Hospers, G A P, Kamphuis, A M, Kapiteijn, E, May, A M, de Meza, M M, Piersma, D, van Rijn, R, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Blokx, W A M, Wouters, M J M & Suijkerbuijk, K P M 2022, ' Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma ', JAMA Oncology, vol. 8, no. 12, pp. 1794-1801 . https://doi.org/10.1001/jamaoncol.2022.5041Test
JAMA oncology, 8(12), 1794-1801. AMER MEDICAL ASSOC
Jama Oncology, 8, 12, pp. 1794-1801
Jama Oncology, 8, 1794-1801

مصطلحات موضوعية: Male, Cancer Research, IPILIMUMAB, NIVOLUMAB, Middle Aged, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Cohort Studies, Immune System Diseases, Oncology, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Humans, FAILURE, Female, Steroids, Melanoma, Immunosuppressive Agents, Retrospective Studies, ANTI-TNF

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b26478643297b0e2ad8b55899ada18aTest
http://hdl.handle.net/1887/3564012Test

المؤلفون: Céleste Lebbé, Ines Pires da Silva, Irene L.M. Reijers, Megan Lyle, Alexander M. Menzies, Alison Weppler, Shahneen Sandhu, Camille L. Gerard, Matteo S. Carlino, Joanna Mangana, Douglas B. Johnson, Patricio Serra-Bellver, Oliver Klein, James R. Patrinely, Andrew Haydon, Tasnia Ahmed, Olivier Michielin, Khang Nguyen, Claudia Trojaniello, Paul Lorigan, Allison Betof Warner, Dan Stout, Clara Allayous, Christian U. Blank, Paolo A. Ascierto, Lisa Zimmer, Serigne Lo, Georgina V. Long

المصدر: The Lancet Oncology. 22:836-847

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Positron Emission Tomography Computed Tomography, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Aged, Retrospective Studies, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Progression-Free Survival, Nivolumab, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9178dd6e7066c6eafdc578a3589333b7Test
https://doi.org/10.1016/s1470-2045Test(21)00097-8

المؤلفون: Irene L. M. Reijers, Robert V. Rawson, Andrew J. Colebatch, Elisa A. Rozeman, Alex M. Menzies, Alexander C. J. van Akkooi, Kerwin F. Shannon, Michel W. Wouters, Robyn P. M. Saw, Winan J. van Houdt, Charlotte L. Zuur, Omgo E. Nieweg, Sydney Ch’ng, W. Martin C. Klop, Andrew J. Spillane, Georgina V. Long, Richard A. Scolyer, Bart A. van de Wiel, Christian U. Blank

المساهمون: Oral and Maxillofacial Surgery

المصدر: JAMA Surgery, 157(4), 335-342. AMER MEDICAL ASSOC
JAMA surgery, 157(4), 335-342. American Medical Association

مصطلحات موضوعية: Male, Skin Neoplasms, Pilot Projects, Middle Aged, Ipilimumab, Neoadjuvant Therapy, Nivolumab, Humans, Lymph Node Excision, Female, Surgery, Lymph Nodes, Prospective Studies, Neoplasm Recurrence, Local, Melanoma, Neoplasm Staging, Retrospective Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83255a1603596ffca3ab7f4e60dc4be4Test
https://doi.org/10.1001/jamasurg.2021.7554Test

المؤلفون: Maurits L. van Montfoort, Daniel J. Vis, Kees Hendricksen, Nick van Dijk, Laura A. Smit, Michiel S. van der Heijden, Henk G. van der Poel, Maries van den Broek, Christian U. Blank, Annemarie Bruining, Yoni Lubeck, Lodewyk F. A. Wessels, Dennis Peters, Pia Kvistborg, Karina Silina, Ton N. Schumacher, Charlotte van Rooijen, Karolina Sikorska, Erik Hooijberg, Annegien Broeks, Bas W.G. van Rhijn, Alberto Gil-Jimenez, Jeantine M de Feijter, Thierry N. Boellaard

المساهمون: University of Zurich, van der Heijden, Michiel S, Graduate School

المصدر: Nature medicine, 26(12), 1839-1844. Nature Publishing Group

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Programmed Cell Death 1 Receptor, 610 Medicine & health, Ipilimumab, 10263 Institute of Experimental Immunology, Gastroenterology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, 1300 General Biochemistry, Genetics and Molecular Biology, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Humans, Medicine, CTLA-4 Antigen, Stage (cooking), Adverse effect, Aged, Neoplasm Staging, business.industry, Antibodies, Monoclonal, General Medicine, Immunotherapy, Middle Aged, Clinical trial, Nivolumab, 030104 developmental biology, 030220 oncology & carcinogenesis, Monoclonal, 570 Life sciences, biology, Female, Urothelium, business, medicine.drug

وصف الملف: 2020_van_Dijk_Nat_Med.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0413d513e2c90df2d190163c39a4236dTest
http://www.scopus.com/inward/record.url?scp=85092396181&partnerID=8YFLogxKTest

المؤلفون: Joris L. Vos, Joris B. W. Elbers, Oscar Krijgsman, Joleen J. H. Traets, Xiaohang Qiao, Anne M. van der Leun, Yoni Lubeck, Iris M. Seignette, Laura A. Smit, Stefan M. Willems, Michiel W. M. van den Brekel, Richard Dirven, M. Baris Karakullukcu, Luc Karssemakers, W. Martin C. Klop, Peter J. F. M. Lohuis, Willem H. Schreuder, Ludi E. Smeele, Lilly-Ann van der Velden, I. Bing Tan, Suzanne Onderwater, Bas Jasperse, Wouter V. Vogel, Abrahim Al-Mamgani, Astrid Keijser, Vincent van der Noort, Annegien Broeks, Erik Hooijberg, Daniel S. Peeper, Ton N. Schumacher, Christian U. Blank, Jan Paul de Boer, John B. A. G. Haanen, Charlotte L. Zuur

المساهمون: Pathology, Otolaryngology / Head & Neck Surgery, Oral and Maxillofacial Surgery / Oral Pathology, Radiology and nuclear medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, RS: GROW - R2 - Basic and Translational Cancer Biology, MUMC+: MA Keel Neus Oorheelkunde (9), KNO, AII - Amsterdam institute for Infection and Immunity, Graduate School, Oral and Maxillofacial Surgery, Other Research, CCA - Cancer Treatment and Quality of Life, Radiotherapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE)

المصدر: Nature Communications, 12(1). NATURE PORTFOLIO
Nature Communications, 12(1):7348. Nature Publishing Group UK
Nature Communications, 12(1):7348. Nature Publishing Group
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature communications, 12(1):7348. Nature Publishing Group
Vos, J L, Elbers, J B W, Krijgsman, O, Traets, J J H, Qiao, X, van der Leun, A M, Lubeck, Y, Seignette, I M, Smit, L A, Willems, S M, van den Brekel, M W M, Dirven, R, Baris Karakullukcu, M, Karssemakers, L, Klop, W M C, Lohuis, P J F M, Schreuder, W H, Smeele, L E, van der Velden, L-A, Bing Tan, I, Onderwater, S, Jasperse, B, Vogel, W V, Al-Mamgani, A, Keijser, A, van der Noort, V, Broeks, A, Hooijberg, E, Peeper, D S, Schumacher, T N, Blank, C U, de Boer, J P, Haanen, J B A G & Zuur, C L 2021, ' Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma ', Nature Communications, vol. 12, no. 1, 7348, pp. 7348 . https://doi.org/10.1038/s41467-021-26472-9Test

مصطلحات موضوعية: Male, Science, SALVAGE SURGERY, General Physics and Astronomy, Article, Phase II trials, General Biochemistry, Genetics and Molecular Biology, Fluorodeoxyglucose F18, Exome Sequencing, Biomarkers, Tumor, Humans, RECURRENT, Head and neck cancer, Immune Checkpoint Inhibitors, Aged, Multidisciplinary, MUTAGENESIS, Squamous Cell Carcinoma of Head and Neck, APOBEC, General Chemistry, Middle Aged, Translational research, CHEMOTHERAPY, OPEN-LABEL, Ipilimumab, CANCER, Neoadjuvant Therapy, stomatognathic diseases, Nivolumab, DURVALUMAB, TREMELIMUMAB, Head and Neck Neoplasms, Positron-Emission Tomography, Tumour immunology, Female, Immunotherapy, RADIOTHERAPY

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500e65e4a1d2b65013f14d4e0fa7a71fTest
http://hdl.handle.net/1887/3279830Test

المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

المؤلفون: Sanne Patiwael, Christian U. Blank, Ton N. Schumacher, Antoni Ribas, John B. A. G. Haanen, Anastasia Gangaev, Daisy Philips, Dirk Schadendorf, Joost H. van den Berg, Maartje W. Rohaan, Bastian Schilling, Elisa A. Rozeman, Pia Kvistborg, Olga I. Isaeva

المصدر: Proc Natl Acad Sci U S A
Proceedings of the National Academy of Sciences of the United States of America, vol 118, iss 43

مصطلحات موضوعية: Male, Receptors, Antigen, T-Cell, alpha-beta, Programmed Cell Death 1 Receptor, Medizin, Epitopes, T-Lymphocyte, CD8-Positive T-Lymphocytes, Lymphocyte Activation, Epitope, Cohort Studies, Epitopes, melanoma-reactive CD8 T cells, Receptors, PD-1, 80 and over, Cytotoxic T cell, CTLA-4 Antigen, Hepatitis A Virus Cellular Receptor 2, Immune Checkpoint Inhibitors, Melanoma, Cancer, alpha-beta, Aged, 80 and over, Multidisciplinary, Middle Aged, Biological Sciences, medicine.anatomical_structure, 5.1 Pharmaceuticals, Antigen, Female, Development of treatments and therapeutic interventions, medicine.symptom, Melanoma-Specific Antigens, Adult, Receptors, CXCR5, T cell, In Vitro Techniques, Clinical Research, medicine, Humans, Aged, business.industry, Compartment (ship), T-Cell, medicine.disease, CXCR5, Blockade, Kinetics, T-Lymphocyte, Mechanism of action, CTLA-4, Cancer research, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994323e563648a11d8ffa0127b701604Test
https://doi.org/10.1073/pnas.2102849118Test

المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel

المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life

المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group

مصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test